6 research outputs found
Perinatal asphyxia: CNS development and deficits with delayed onset
Perinatal asphyxia constitutes a prototype of obstetric complications occurring when pulmonary
oxygenation is delayed or interrupted. The primary insult relates to the duration of the period
lacking oxygenation, leading to death if not re-established. Re-oxygenation leads to a secondary
insult, related to a cascade of biochemical events required for restoring proper function. Perinatal
asphyxia interferes with neonatal development, resulting in long-term deficits associated to mental
and neurological diseases with delayed clinical onset, by mechanisms not yet clarified.
In the experimental scenario, the effects observed long after perinatal asphyxia have been explained
by over expression of sentinel proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1),
competing for NAD+ during re-oxygenation, leading to the idea that sentinel protein inhibition
constitutes a suitable therapeutic strategy. Asphyxia induces transcriptional activation of proinflammatory
factors, in tandem with PARP-1 overactivation, and pharmacologically induced
PARP-1 inhibition also down-regulates the expression of proinflammatory cytokines.
Nicotinamide has been proposed as a suitable PARP-1 inhibitor. Its effect has been studied in
an experimental model of global hypoxia in rats. In that model, the insult is induced by immersing
rat foetuses into a water bath for various periods of time. Following asphyxia, the pups are
delivered, treated, and nursed by surrogate dams, pending further experiments. Nicotinamide
rapidly distributes into the brain following systemic administration, reaching steady state
concentrations sufficient to inhibit PARP-1 activity for several hours, preventing several of the
long-term consequences of perinatal asphyxia, supporting the idea that it constitutes a lead for
exploring compounds with similar or better pharmacological profiles
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins
Delivery is a stressful and risky event menacing the newborn. The mother-dependent respiration has to be replaced by autonomous pulmonary breathing immediately after delivery. If delayed, it may lead to deficient oxygen supply compromising survival and development of the central nervous system. Lack of oxygen availability gives rise to depletion of NAD+ tissue stores, decrease of ATP formation, weakening of the electron transport pump and anaerobic metabolism and acidosis, leading necessarily to death if oxygenation is not promptly re-established. Re-oxygenation triggers a cascade of compensatory biochemical events to restore function, which may be accompanied by improper homeostasis and oxidative stress. Consequences may be incomplete recovery, or excess reactions that worsen the biological outcome by disturbed metabolism and/or imbalance produced by over-expression of alternative metabolic pathways. Perinatal asphyxia has been associated with severe neurological and psychiatric sequelae with delayed clinical onset. No specific treatments have yet been established. In the clinical setting, after resuscitation of an infant with birth asphyxia, the emphasis is on supportive therapy. Several interventions have been proposed to attenuate secondary neuronal injuries elicited by asphyxia, including hypothermia. Although promising, the clinical efficacy of hypothermia has not been fully demonstrated. It is evident that new approaches are warranted. The purpose of this review is to discuss the concept of sentinel proteins as targets for neuroprotection. Several sentinel proteins have been described to protect the integrity of the genome (e.g. PARP-1; XRCC1; DNA ligase IIIα; DNA polymerase β, ERCC2, DNA-dependent protein kinases). They act by eliciting metabolic cascades leading to (i) activation of cell survival and neurotrophic pathways; (ii) early and delayed programmed cell death, and (iii) promotion of cell proliferation, differentiation, neuritogenesis and synaptogenesis. It is proposed that sentinel proteins can be used as markers for characterising long-term effects of perinatal asphyxia, and as targets for novel therapeutic development and innovative strategies for neonatal care
The Gaia mission
Gaia is a cornerstone mission in the science programme of the EuropeanSpace Agency (ESA). The spacecraft construction was approved in 2006, following a study in which the original interferometric concept was changed to a direct-imaging approach. Both the spacecraft and the payload were built by European industry. The involvement of the scientific community focusses on data processing for which the international Gaia Data Processing and Analysis Consortium (DPAC) was selected in 2007. Gaia was launched on 19 December 2013 and arrived at its operating point, the second Lagrange point of the Sun-Earth-Moon system, a few weeks later. The commissioning of the spacecraft and payload was completed on 19 July 2014. The nominal five-year mission started with four weeks of special, ecliptic-pole scanning and subsequently transferred into full-sky scanning mode. We recall the scientific goals of Gaia and give a description of the as-built spacecraft that is currently (mid-2016) being operated to achieve these goals. We pay special attention to the payload module, the performance of which is closely related to the scientific performance of the mission. We provide a summary of the commissioning activities and findings, followed by a description of the routine operational mode. We summarise scientific performance estimates on the basis of in-orbit operations. Several intermediate Gaia data releases are planned and the data can be retrieved from the Gaia Archive, which is available through the Gaia home page. http://www.cosmos.esa.int/gai
Further studies on the hypothesis of PARP-1 inhibition as a strategy for lessening the long-term effects produced by perinatal asphyxia: Effects of nicotinamide and theophylline on PARP-1 activity in brain and peripheral tissue
Oxygen interruption leads to death when reoxygenation is not promptly re-established. Re-oxygenation triggers a cascade of biochemical events for restoring function at the cost of improper homeostasis. The effects observed long after perinatal asphyxia (PA) have been explained by over-expression of sentinel proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1), competing for NAD+ during re-oxygenation, leading to the idea that sentinel protein inhibition constitutes a therapeutic strategy. We studied the effects of nicotinamide and theophylline on PARP-1 activity assayed in brain and peripheral (heart) rat tissue 1-24 h after birth, as well as on changes in behaviour and monoamine neurotransmission in adult rats. PA was induced by immersing rat foetuses into a water bath for 0 or 21 min. After resuscitation, the pups were treated with nicotinamide (0.8 mmol/kg, i.p.), theophylline (0.14 mmol/kg, i.p.) or saline (0.9% NaCl) and nurtured by surrogate dams, pending behavioural and mic